Latest Breaking News On - Company spongilla - Page 1 : comparemela.com

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track Dermata continues discussions with potential botulinum toxin partners for DMT410 Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis -SAN DIEGO, CA / ACCESSWIRE / May 15, 202.

San diegoUnited statesGerry proehlSean proehlPartnership discussionsCompany spongillaExchange commissionSpongilla treatment of acne researchDermata therapeutics incAcne researchDermata therapeuticsChief executivePrivate securities litigation reform actEnded march

Dermata Therapeutics Provides Corporate Update and Reports First Quarter

Dermata Therapeutics Provides Corporate Update and Reports First Quarter
pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesGerry proehlDermata therapeutics incCompany spongillaNews networkSpongilla treatment of acne researchPartnership discussionsTherapeutics provides corporate updateReports first quarterAcne researchDermata therapeuticsChief executiveUpcoming milestonesLooking statements

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesSan diegoSean proehlGerry proehlExchange commissionPartnership discussionsSpongilla treatment of acne researchDermata therapeutics incCompany spongillaAcne researchDermata therapeuticsChief executivePrivate securities litigation reform actEnded marchIhr portfolio

Dermata Therapeutics : Provides Corporate Update and Reports First Quarter 2024 Financial Results - Form 8-K

Dermata Therapeutics : Provides Corporate Update and Reports First Quarter 2024 Financial Results - Form 8-K
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoGerry proehlSean proehlExchange commissionPartnership discussionsDermata therapeutics incCompany spongillaSpongilla treatment of acne researchDermata therapeutics provides corporate updateReports first quarterAcne researchChief executivePrivate securities litigation reform actEnded march

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for

- This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis The Company is currently discussing partnership opportunities to advance development of DMT410 In 2022, the Japanese prevalence of hyperhidrosis was 10%, with approximat.

United statesSan diegoSean proehlGerry proehlDermata therapeutics incCompany spongillaExchange commissionDermata therapeuticsJapanese patentPrivate securities litigation reform act